The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
about
New antiresorptive therapies for postmenopausal osteoporosisOptimization of triazine nitriles as rhodesain inhibitors: structure-activity relationships, bioisosteric imidazopyridine nitriles, and X-ray crystal structure analysis with human cathepsin LCathepsin K inhibitors for osteoporosis and potential off-target effectsDrug discovery for neglected tropical diseases at the Sandler Center.Cysteine Protease Cathepsins in Atherosclerosis and Abdominal Aortic Aneurysm.Cysteine Cathepsin Inhibitors as Anti-Ebola Agents.Potential role of odanacatib in the treatment of osteoporosis.Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitorsTherapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?Reversible cysteine protease inhibitors show promise for a Chagas disease cure.Cathepsin L in metastatic bone disease: therapeutic implications.Inhibitors of cathepsin K: a patent review (2004 - 2010).Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.Drug discovery for a new generation of covalent drugs.Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications.Cathepsin S: therapeutic, diagnostic, and prognostic potential.Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' diseaseDesign, characterization and cellular uptake studies of fluorescence-labeled prototypic cathepsin inhibitors.
P2860
Q27014775-53832299-D1AB-482F-A3C4-F65BED620FFAQ27684569-D1E510BD-FB16-4BB5-A263-4C7EE53BA112Q29042565-1A281452-961F-4E42-8C37-54D87C12592EQ35419266-E1195A83-3378-4BED-9939-86B508BE1DB1Q35883165-61EAAF3E-732B-4054-9842-6F02E983E4BEQ36062150-ECDA2BA1-42E1-439A-BF44-8109957C94CDQ36136239-1F490A48-ED76-47E6-9B6E-366F948CA91EQ36286306-7014D8DA-2381-402A-BEE2-BAA79A4490F2Q37056336-4D59FE97-1741-4536-B5DF-37DDC4BF3264Q37058788-62A1EEA1-53B7-4FA8-A727-607ADF4ADEF5Q37428071-FCE245E6-25CB-4086-800E-AF73C56CCEC6Q37544765-1AACEE8C-AE0B-4625-AA54-5FD16A1AFD2EQ37724780-0F5B0449-16E6-403A-949C-5E4272688D03Q37933395-C3E8EB31-3DDA-4E21-BF0B-F581B7BB23CBQ37998091-A6D3817F-439D-4608-AA35-F485A98F37A7Q38011256-2989EDEE-0217-4A31-B72C-0403385A831EQ38012166-CB83967B-E7BE-44F2-A73B-8143C73FAAF8Q38420668-4F4B6EEE-7AD1-44A7-996B-F36953A25087Q42545221-C308AB38-0F0D-4F0D-B960-8D9642061981Q53372260-9204A81A-5067-4151-9C46-199AD7736A8B
P2860
The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
@ast
The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
@en
type
label
The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
@ast
The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
@en
prefLabel
The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
@ast
The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
@en
P2860
P356
P1433
P1476
The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
@en
P2093
M David Percival
W Cameron Black
P2860
P304
P356
10.1002/CBIC.200600149
P577
2006-10-01T00:00:00Z